+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Alpha-Antitrypsin Deficiency Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768300
  • Report
  • April 2019
  • Region: Global
  • 54 pages
  • VPA Research

FEATURED COMPANIES

  • Bayer AG
  • Cinven Ltd
  • CSL Ltd
  • Grifols SA
  • Kamada Ltd
  • Shire Plc
The global clinical trial report- “2019 Alpha-Antitrypsin Deficiency Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Alpha-Antitrypsin Deficiency. It presents in-depth analysis of Alpha-Antitrypsin Deficiency clinical trials across markets and companies. The research work is for providing complete understanding into trends in Alpha-Antitrypsin Deficiency.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Alpha-Antitrypsin Deficiency clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Alpha-Antitrypsin Deficiency

The research work is prepared through extensive and continuous research on Alpha-Antitrypsin Deficiency trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Alpha-Antitrypsin Deficiency patients are identified
  • The report includes panorama of Alpha-Antitrypsin Deficiency clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Alpha-Antitrypsin Deficiency clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer AG
  • Cinven Ltd
  • CSL Ltd
  • Grifols SA
  • Kamada Ltd
  • Shire Plc
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Alpha-Antitrypsin Deficiency Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Alpha-Antitrypsin Deficiency Clinical Trials by Region
2.2.2 Average Enrollment of Alpha-Antitrypsin Deficiency Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Alpha-Antitrypsin Deficiency Treatment, 2019

3. Region wise Alpha-Antitrypsin Deficiency Clinical Trials
3.1 Asia Pacific Alpha-Antitrypsin Deficiency Clinical Trials by Country
3.2 Europe Alpha-Antitrypsin Deficiency Clinical Trials by Country
3.3 North America Alpha-Antitrypsin Deficiency Clinical Trials by Country
3.4 Middle East and Africa Alpha-Antitrypsin Deficiency Clinical Trials by Country
3.5 South and Central America Alpha-Antitrypsin Deficiency Clinical Trials by Country

4. Alpha-Antitrypsin Deficiency Clinical Trial Trends
4.1 Start Year wise Alpha-Antitrypsin Deficiency Clinical Trials
4.2 Phase wise Alpha-Antitrypsin Deficiency Clinical Trials
4.3 Trial Status wise Alpha-Antitrypsin Deficiency Clinical Trials
4.4 Trial Type wise Alpha-Antitrypsin Deficiency Clinical Trials

5. Alpha-Antitrypsin Deficiency Average Enrollment Trends
5.1 Average Enrollment in Alpha-Antitrypsin Deficiency Trials by Year
5.2 Average Enrollment in Alpha-Antitrypsin Deficiency Trials by Phase
5.3 Average Enrollment in Alpha-Antitrypsin Deficiency Trials by Status
5.4 Average Enrollment in Alpha-Antitrypsin Deficiency Trials by Type of Trial

6. Companies Participating in Alpha-Antitrypsin Deficiency Clinical Trials
6.1 Alpha-Antitrypsin Deficiency Trials by Sponsor Type
6.2 Alpha-Antitrypsin Deficiency Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Alpha-Antitrypsin Deficiency Trials- Phase 1
7.2 Alpha-Antitrypsin Deficiency Trials- Phase 2
7.3 Alpha-Antitrypsin Deficiency Trials- Phase 3
7.4 Alpha-Antitrypsin Deficiency Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Alpha-Antitrypsin Deficiency Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Figure 5: Europe - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Figure 7: North America - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Figure 9: Alpha-Antitrypsin Deficiency Clinical Trials by Phase
Figure 10: Alpha-Antitrypsin Deficiency Clinical Trials by Trial Status
Figure 11: Alpha-Antitrypsin Deficiency Clinical Trials by Type
Figure 12: Alpha-Antitrypsin Deficiency Clinical Trials by Sponsor Type
Figure 13: Alpha-Antitrypsin Deficiency Clinical Trials by Leading Sponsors
Figure 14: Alpha-Antitrypsin Deficiency Average Enrollment by Phase
Figure 15: Alpha-Antitrypsin Deficiency Average Enrollment by Trial Status
Figure 16: Alpha-Antitrypsin Deficiency Average Enrollment by Type
Figure 17: Alpha-Antitrypsin Deficiency- Average Enrolment by Type of Sponsors
Figure 18: Alpha-Antitrypsin Deficiency- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Alpha-Antitrypsin Deficiency Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Table 5: Europe - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Table 7: North America - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Alpha-Antitrypsin Deficiency Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Alpha-Antitrypsin Deficiency Average Enrollment by Phase
Table 15: Alpha-Antitrypsin Deficiency Average Enrollment by Trial Status
Table 16: Alpha-Antitrypsin Deficiency Average Enrollment by Type
Table 17: Alpha-Antitrypsin Deficiency- Average Enrolment by Type of Sponsors
Table 18: Alpha-Antitrypsin Deficiency- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Alnylam Pharmaceuticals Inc
  • Applied Genetic Technologies Corp
  • Arriva Pharmaceuticals Inc
  • Arrowhead Pharmaceuticals Inc
  • Bayer AG
  • Cinven Ltd
  • CSL Ltd
  • Grifols SA
  • Kamada Ltd
  • Shire Plc
Note: Product cover images may vary from those shown
Adroll
adroll